Phospho-PLK1 (S137) Antibody

What is PLK1 and why is S137 phosphorylation significant?

PLK1 (Polo-like kinase 1) is a serine/threonine protein kinase that regulates multiple processes during mitosis. It is activated by phosphorylation at the G2/M phase boundary and plays crucial roles in promoting mitotic entry through activation of Cdc25C and nuclear import of cyclin B1, which together activate Cdc2/cyclin B kinase . Phosphorylation at serine 137 (S137) is particularly significant as it increases PLK1 activity and has been implicated in cell survival during mitochondrial dysfunction . S137 is located in the kinase domain, specifically within the short spacer region of a bipartite nuclear localization signal that has been shown to be important for cell cycle progression .

How does PLK1 S137 phosphorylation differ from T210 phosphorylation?

While both S137 and T210 phosphorylation sites are located in the kinase domain of PLK1, they have distinct functional roles and regulatory mechanisms:

S137 phosphorylation has been reported to have a dominant effect over T210 phosphorylation and to increase the G1 population of cells . Unlike T210, where mutation to non-phosphorylatable form (T210V) results in a Plk1-null phenotype, some studies suggest S137A mutation does not completely abolish essential Plk1 functions .

What techniques are recommended for detecting PLK1 S137 phosphorylation?

Western blotting is the primary technique validated for detecting PLK1 S137 phosphorylation using phospho-specific antibodies . When designing experiments to detect this phosphorylation:

• Select an appropriate phospho-specific antibody such as rabbit polyclonal anti-PLK1 (phospho S137) antibodies

• Use appropriate dilutions (e.g., 1/500 dilution for Western blot)

• Include proper controls:

  • Total PLK1 protein levels (using antibodies recognizing PLK1 regardless of phosphorylation status)

  • Positive controls (mitotic cell extracts where phosphorylation is expected to be high)

  • Negative controls (extracts treated with phosphatase)

  • Specificity controls (comparing with other phosphorylation sites like T210)

What is the relationship between PLK2 and PLK1 S137 phosphorylation?

PLK2 has been identified as a kinase that preferentially phosphorylates PLK1 at S137. This relationship was discovered through a kinase substrate screen using purified PLK2, which identified the optimal peptide substrate belonging to PLK1, specifically at Ser-137 . The evidence supporting this relationship includes:

• In vitro phosphorylation assays show strong increases in PLK1-S137-P immunoreactivity in the presence of PLK2

• PLK2 shows preferential phosphorylation of S137 over T210

• Cellular studies demonstrate concordance between PLK2 and PLK1-S137-P levels

• PLK2 depletion in SCO2-/- cells reduces PLK1-S137 phosphorylation

• PLK2 overexpression in SCO2+/+ cells increases PLK1-S137 phosphorylation

This PLK2-mediated phosphorylation of PLK1-S137 has been implicated as an important adaptive mechanism for cell survival during mitochondrial dysfunction, regulating the G1-S phase checkpoint .

How is PLK1 S137 phosphorylation regulated in response to DNA damage?

PLK1 S137 phosphorylation is subject to regulation by DNA damage response pathways:

• DNA damage prevents phosphorylation of PLK1 at both S137 and T210 in asynchronous cells but not in mitotic cells

• The inhibition of PLK1 phosphorylation in response to DNA damage involves ATM/ATR-dependent checkpoint pathways

• Inhibitors of ATM/ATR and Chk1/Chk2 protein kinases can avert the inhibition of PLK1 phosphorylation in response to DNA damage

These findings suggest that DNA damage checkpoints participate in regulating the signaling pathways upstream of PLK1. The differential response in asynchronous versus mitotic cells indicates cell cycle-dependent regulation of this phosphorylation under DNA damage conditions .

What are the contradictions in the literature regarding the essentiality of S137 phosphorylation?

Research on the functional significance of S137 phosphorylation has produced some seemingly contradictory results:

These contradictions suggest that S137 phosphorylation may play critical roles only in specific contexts, such as DNA damage response or mitochondrial dysfunction, rather than being universally essential for all PLK1 functions .

How does PLK1 S137 phosphorylation contribute to mitochondrial dysfunction response?

PLK1 S137 phosphorylation appears to be a key mediator in the cellular response to mitochondrial dysfunction:

• SCO2-/- cells (with mitochondrial dysfunction) show higher PLK1-S137-P levels despite lower total PLK1 protein compared to SCO2+/+ cells

• When respiration is rescued by stably re-expressing SCO2 cDNA in SCO2-/- cells, there is a parallel decrease in the levels of PLK2 and PLK1-S137-P

• The PLK1-S137D mutant (mimicking constitutive phosphorylation) markedly increases colony formation in PLK2-depleted SCO2-/- cells

This suggests that phosphorylation of PLK1-S137 by PLK2 represents an important adaptive mechanism for cell survival during mitochondrial dysfunction, potentially through regulation of the G1-S phase checkpoint . This pathway could serve as a potential target for therapeutic intervention, as cancer cells often display mitochondrial defects .

What experimental design considerations are crucial when using phospho-specific antibodies for PLK1 S137?

When designing experiments using phospho-specific antibodies for PLK1 S137:

• Antibody validation:

  • Confirm antibody specificity using phosphatase treatment controls

  • Validate using PLK1 S137A mutant cells as negative controls

  • Test cross-reactivity with other phosphorylation sites (especially T210)

• Cell cycle synchronization:

  • Since S137 phosphorylation occurs during mitosis, proper cell cycle synchronization is essential

  • Compare asynchronous and mitotic cell populations

• DNA damage considerations:

  • Account for DNA damage response effects on S137 phosphorylation

  • Include appropriate DNA damage agents and ATM/ATR inhibitors as controls

• Mitochondrial status assessment:

  • Given the relationship between mitochondrial dysfunction and S137 phosphorylation, assess mitochondrial function

  • Consider using cells with varying degrees of mitochondrial impairment (e.g., SCO2+/+, SCO2+/-, SCO2-/- models)

• PLK2 expression analysis:

  • Quantify PLK2 levels in parallel with PLK1-S137-P

  • Consider PLK2 knockdown or overexpression experiments to validate relationships

How can researchers functionally assess the impact of PLK1 S137 phosphorylation?

Several methodological approaches can be used to assess the functional significance of PLK1 S137 phosphorylation:

• Phosphomimetic and non-phosphorylatable mutants:

  • Create S137A (non-phosphorylatable) and S137D (phosphomimetic) mutants of PLK1

  • Assess their impact on PLK1 kinase activity in vitro

  • Evaluate their ability to rescue PLK1-dependent phenotypes in PLK1-depleted or inhibited cells

• Cell cycle analysis:

  • Measure G1, S, G2/M populations in cells expressing different PLK1 S137 mutants

  • Track cell cycle progression using time-lapse microscopy

  • Assess mitotic entry/exit timing and chromosome segregation

• Survival and proliferation assays:

  • Colony formation assays with cells expressing different PLK1 S137 mutants

  • Cell proliferation measurements under normal and stress conditions

  • Long-term viability studies

• Response to cellular stresses:

  • Assess how S137 phosphorylation affects cell response to DNA damage

  • Evaluate the role in mitochondrial dysfunction scenarios

  • Test sensitivity to various cellular stressors

What is the current understanding of the interplay between different PLK1 post-translational modifications?

PLK1 undergoes multiple post-translational modifications (PTMs) that collectively regulate its function:

• Phosphorylation sites:

  • S137 and T210 are key phosphorylation sites in the kinase domain

  • T214 and Y217 also impact PLK1 function, with T214V mutation causing defects in mitotic progression

  • S326 phosphorylation promotes progression through mitosis

• Ubiquitination:

  • K492 ubiquitination has been suggested to be important for removal of PLK1 from kinetochores

  • Some studies show K492R mutation results in mitotic delay and increased apoptosis, though with low penetrance

• Hierarchical relationships:

  • S137 phosphorylation has been reported to have a dominant effect over T210 phosphorylation

  • Different modifications may have context-dependent importance (e.g., S137 may be more critical in DNA damage or mitochondrial dysfunction)

• PTM interactions:

  • A comprehensive study identified 34 phosphorylation and ubiquitination modifications on human PLK1

  • Most single modifications appear non-essential under ordinary conditions, with key exceptions (T210, T214)

  • The true functional significance of many PTMs may only be revealed under specific stress conditions or in combination with other modifications

What are the key outstanding questions regarding PLK1 S137 phosphorylation?

Several important questions remain unresolved in the field:

• What is the precise molecular mechanism by which S137 phosphorylation alters PLK1 activity and substrate specificity?

• Are there other kinases besides PLK2 that can phosphorylate PLK1 at S137 under specific conditions?

• How does the interplay between S137 and T210 phosphorylation dynamically regulate PLK1 during different cell cycle phases?

• What is the three-dimensional structural impact of S137 phosphorylation on PLK1 conformation?

• How conserved is the S137 phosphorylation mechanism across different species and cell types?

• Are there specific PLK1 substrates that are preferentially affected by S137 phosphorylation status?

How might PLK1 S137 phosphorylation be relevant to cancer research?

The relationship between PLK1 S137 phosphorylation and cancer presents several intriguing research directions:

• Cancer cell adaptation:

  • Since PLK1-S137 phosphorylation mediates cell survival in mitochondrial dysfunction, and cancer cells often display mitochondrial defects, this signaling pathway could serve as a potential target for therapeutic intervention

• PLK2-PLK1 axis:

  • The role of PLK2 in tumorigenesis is less clear than PLK1

  • PLK2 transcription is regulated by p53, with both stimulatory and inhibitory elements

  • PLK2 has been shown to be epigenetically silenced in high-grade B-cell lymphomas, implicating it as a tumor suppressor in that context

  • Some primary human cancers express higher levels of PLK2 compared to normal tissues

• Checkpoint regulation:

  • The inhibition of PLK1 S137 phosphorylation by DNA damage checkpoints suggests potential roles in genomic stability

  • Understanding how cancer cells might bypass this regulation could reveal therapeutic vulnerabilities

• Cell type specificity:

  • The role of PLK2 and PLK1 S137 phosphorylation may depend on cell type and context

  • Focused studies examining this interaction in isogenic human cancer cell lines with specific disruption of important cell cycle regulatory genes could advance understanding of these pathways

What controls should be included when validating phospho-specific PLK1 S137 antibodies?

To properly validate phospho-specific PLK1 S137 antibodies for research applications:

• Specificity controls:

  • Test antibody reactivity with wild-type PLK1 versus S137A mutant

  • Compare with phospho-T210 specific antibodies to confirm site specificity

  • Pre-treat lysates with lambda phosphatase to confirm phospho-specificity

• Sample preparation controls:

  • Include mitotic enriched samples (high phosphorylation expected)

  • Compare with G1/S phase samples (lower phosphorylation expected)

  • Include DNA damage treated samples (reduced phosphorylation expected in asynchronous cells)

• Technical controls:

  • Test multiple antibody dilutions to determine optimal working concentration

  • Include loading controls to normalize for total protein content

  • Test multiple detection methods if possible (Western blot, immunoprecipitation)

• Positive biological controls:

  • Samples with PLK2 overexpression (expected to increase S137 phosphorylation)

  • Mitotic cell extracts (where phosphorylation naturally occurs)

These rigorous validation steps ensure that experimental observations truly reflect the biological status of PLK1 S137 phosphorylation rather than technical artifacts.

How can researchers design experiments to address contradictions in the literature regarding PLK1 S137 function?

To address the contradictory findings regarding PLK1 S137 phosphorylation:

• Standardized experimental systems:

  • Use multiple cell lines with documented p53 status

  • Apply consistent methods for depleting endogenous PLK1 and expressing mutants

  • Compare results across normal and stress conditions (DNA damage, mitochondrial dysfunction)

• Combinatorial mutation analysis:

  • Test S137 mutations in combination with other PLK1 modifications

  • Evaluate phenotypes across multiple functional assays

  • Quantify relative importance in different contexts

• Temporal resolution:

  • Implement live-cell imaging with phospho-specific sensors

  • Track S137 phosphorylation dynamics throughout the cell cycle

  • Correlate with cellular phenotypes in real-time

• Context-dependent analysis:

  • Systematically vary experimental conditions (oxygen levels, nutrient availability, genotoxic stress)

  • Quantify relative importance of S137 phosphorylation under each condition

  • Develop predictive models of when S137 phosphorylation becomes critical